| Name | Title | Contact Details |
|---|
Established in 2019 when Anne Arundel Medical Center and Doctors Community Medical Center came together to form one health system, Luminis Health is sparking a new path forward. With 595 beds across three hospitals, we currently serve seven counties in the heart of central Maryland. Our team is made up of more than 9,000 medical staff, employees and volunteers – all of whom are committed to illuminating new possibilities in health care and for our community. Thanks to them, U.S. News & World Report has deemed AAMC a top hospital in the region and the Maryland Institute for Emergency Medical Services Systems has named DCMC a primary stroke center – just to name a few accolades. We have also earned national recognition in cancer care, stroke care, innovation and patient satisfaction. We can`t wait to see what`s next.
We are a Louisville-based healthcare holdings company with physical therapy partners in over 530+ clinics across 29 states. Confluent Health transforms physical health by effectively meeting the needs of the communities we serve: patients, employers, payors, students, and providers. Primarily focusing on physical and occupational therapy, which provides long-lasting outcomes without surgery, medication, or diagnostic imaging, Confluent Health companies aid in reducing healthcare expenditures and increasing overall population health. Our companies focus on the following services: * Outpatient Physical and Occupational Therapy * Workplace Injury Prevention Through Early Intervention and Employee Screening * Advanced and Entry-Level Education for Physical Therapists and Occupational Therapists No matter what clinic you`re at or where you`re being seen, we have one goal - to get you back to your life, faster.
The Hearing And Speech Agency Of Metropolitan Baltimore Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Baltimore, MD. To find more information about The Hearing And Speech Agency Of Metropolitan Baltimore Inc, please visit www.hasa.org
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.